Welcome to our dedicated page for Genmab A/S SEC filings (Ticker: GNMSF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genmab A/S filings document the disclosures of a foreign private issuer in biotechnology, with Form 6-K reports covering interim financial results, company announcements and exhibits incorporated by reference into S-8 registration statements. The filings describe antibody-medicine revenue drivers, collaboration royalties related to DARZALEX and Kesimpta, and pipeline disclosures for programs including EPKINLY, Rina-S and petosemtamab.
The company’s regulatory reports also record Danish capital-markets announcements, major shareholder notifications, share-capital reductions, voting-rights disclosures and governance-related corporate actions. These filings frame Genmab’s public-company record around operating performance, capital structure, ownership reporting, product-regulatory updates and risks tied to developing and commercializing antibody therapeutics.
Genmab A/S is making a very small capital increase by issuing 185 new shares following the exercise of employee warrants. The shares are subscribed in cash at DKK 1,334.50 per share, providing the company with approximately DKK 0.2 million in proceeds and representing less than 0.001% of its share capital.
After this increase, Genmab’s total nominal share capital is DKK 62,353,252, divided into 62,353,252 ordinary shares with one vote each. The new shares carry standard rights, including dividends from the date of subscription, and will be listed on Nasdaq Copenhagen once registered with the Danish Business Authority.
Genmab A/S is making a very small capital increase by issuing 185 new shares following the exercise of employee warrants. The shares are subscribed in cash at DKK 1,334.50 per share, providing the company with approximately DKK 0.2 million in proceeds and representing less than 0.001% of its share capital.
After this increase, Genmab’s total nominal share capital is DKK 62,353,252, divided into 62,353,252 ordinary shares with one vote each. The new shares carry standard rights, including dividends from the date of subscription, and will be listed on Nasdaq Copenhagen once registered with the Danish Business Authority.
Genmab A/S reports a major shareholder status change for Orbis Investment Management Limited under Section 30 of the Danish Capital Markets Act. As of June 12, 2026, Orbis controls the voting rights to 3,112,476 Genmab shares, equal to 4.99% of the company’s share capital and voting rights.
The attached notification shows this holding decreased from 5.0783% of voting rights on a previous date. The Allan & Gill Gray Foundation is listed as the person subject to the notification obligation, with the Orbis group entities identified in the ownership chain.
Genmab A/S reports a major shareholder status change for Orbis Investment Management Limited under Section 30 of the Danish Capital Markets Act. As of June 12, 2026, Orbis controls the voting rights to 3,112,476 Genmab shares, equal to 4.99% of the company’s share capital and voting rights.
The attached notification shows this holding decreased from 5.0783% of voting rights on a previous date. The Allan & Gill Gray Foundation is listed as the person subject to the notification obligation, with the Orbis group entities identified in the ownership chain.
Genmab A/S reports that its Board of Directors has granted 15,894 restricted stock units and 15,494 warrants to employees of the company and its subsidiaries. Each restricted stock unit is awarded cost-free, has a fair value equal to the DKK 1,616.50 closing share price on the grant date, and will vest after three years, subject to program conditions.
Each warrant is also awarded cost-free, carries an exercise price of DKK 1,616.50 per share and a calculated fair value of DKK 534.23 using the Black-Scholes formula. The warrants vest three years after grant and expire seven years after the grant date, under Genmab’s existing warrant program.
Genmab A/S reports that its Board of Directors has granted 15,894 restricted stock units and 15,494 warrants to employees of the company and its subsidiaries. Each restricted stock unit is awarded cost-free, has a fair value equal to the DKK 1,616.50 closing share price on the grant date, and will vest after three years, subject to program conditions.
Each warrant is also awarded cost-free, carries an exercise price of DKK 1,616.50 per share and a calculated fair value of DKK 534.23 using the Black-Scholes formula. The warrants vest three years after grant and expire seven years after the grant date, under Genmab’s existing warrant program.
Genmab A/S filed a Form 6-K reporting insider trading activity by a managerial employee. Board member Michael Kavanagh sold 526 Genmab shares on May 29, 2026 on NASDAQ Copenhagen at a price of DKK 1,734.75 per share.
The filing is made under European Market Abuse Regulation Article 19 and is incorporated by reference into several of Genmab’s employee share plan registration statements on Form S-8. Genmab also reiterates its focus on antibody-based medicines and includes standard forward-looking statement risk disclosures.
Genmab A/S filed a Form 6-K reporting insider trading activity by a managerial employee. Board member Michael Kavanagh sold 526 Genmab shares on May 29, 2026 on NASDAQ Copenhagen at a price of DKK 1,734.75 per share.
The filing is made under European Market Abuse Regulation Article 19 and is incorporated by reference into several of Genmab’s employee share plan registration statements on Form S-8. Genmab also reiterates its focus on antibody-based medicines and includes standard forward-looking statement risk disclosures.
Genmab A/S ownership disclosure: two institutional investors filed an amended Schedule 13G/A reporting beneficial ownership positions in Genmab common stock. The filing shows 3,557,484 shares beneficially owned representing 5.5% of the class and identifies Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd as the reporting persons.
The filing breaks the holdings down by voting and dispositive power: Orbis holds 3,549,674 shares with sole voting and dispositive power, and Allan Gray Australia holds 7,810 shares with sole voting and dispositive power. The filing states the reporting persons are non-U.S. institutions functionally equivalent to an investment adviser and disclaims group beneficial ownership.
Genmab A/S ownership disclosure: two institutional investors filed an amended Schedule 13G/A reporting beneficial ownership positions in Genmab common stock. The filing shows 3,557,484 shares beneficially owned representing 5.5% of the class and identifies Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd as the reporting persons.
The filing breaks the holdings down by voting and dispositive power: Orbis holds 3,549,674 shares with sole voting and dispositive power, and Allan Gray Australia holds 7,810 shares with sole voting and dispositive power. The filing states the reporting persons are non-U.S. institutions functionally equivalent to an investment adviser and disclaims group beneficial ownership.
Genmab A/S will increase its share capital by 2,346 shares after employees exercised warrants, a very small change equal to about 0.004% of the company’s share capital.
The new shares were subscribed for cash at prices between DKK 1,147.50 and DKK 1,362.50 per share, generating approximately DKK 3.0 million in proceeds for Genmab. These are ordinary shares with standard rights, including dividends, from the date of subscription.
After the capital increase, Genmab’s total nominal share capital will be DKK 62,353,067, corresponding to 62,353,067 shares with one vote each. The new shares will be listed on Nasdaq Copenhagen once the increase is registered with the Danish Business Authority.
Genmab A/S will increase its share capital by 2,346 shares after employees exercised warrants, a very small change equal to about 0.004% of the company’s share capital.
The new shares were subscribed for cash at prices between DKK 1,147.50 and DKK 1,362.50 per share, generating approximately DKK 3.0 million in proceeds for Genmab. These are ordinary shares with standard rights, including dividends, from the date of subscription.
After the capital increase, Genmab’s total nominal share capital will be DKK 62,353,067, corresponding to 62,353,067 shares with one vote each. The new shares will be listed on Nasdaq Copenhagen once the increase is registered with the Danish Business Authority.
Genmab A/S reports a change in a major shareholder’s position. Orbis Investment Management Limited informed Genmab that, as of May 8, 2026, it controlled voting rights attached to 3,166,357 Genmab shares, equal to 5.08% of the company’s share capital and voting rights.
A related Danish major holdings notification shows the Allan & Gill Gray Foundation group increasing its voting rights in Genmab to 5.0783%, up from 4.8471%, out of a total of 62,350,721 voting rights in the issuer. The filing also confirms there are no additional holdings via financial instruments.
Genmab A/S reports a change in a major shareholder’s position. Orbis Investment Management Limited informed Genmab that, as of May 8, 2026, it controlled voting rights attached to 3,166,357 Genmab shares, equal to 5.08% of the company’s share capital and voting rights.
A related Danish major holdings notification shows the Allan & Gill Gray Foundation group increasing its voting rights in Genmab to 5.0783%, up from 4.8471%, out of a total of 62,350,721 voting rights in the issuer. The filing also confirms there are no additional holdings via financial instruments.